3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Breast Neoplasms
113
Colorectal Neoplasms
73
Stomach Neoplasms
48
Pancreatic Neoplasms
45
Rectal Neoplasms
40
Neoplasms
29
Neoplasm Metastasis
29
Colonic Neoplasms
18
Esophageal Neoplasms
16
Triple Negative Breast Neoplasms
13
Adenocarcinoma
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Gallbladder Neoplasms
9
Bile Duct Neoplasms
8
Brain Neoplasms
7
Adenocarcinoma Of Esophagus
7
Liver Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
5
Cholangiocarcinoma
5
Breast Neoplasms, Male
5
Somatostatinoma
4
Head and Neck Neoplasms
4
Carcinoma, Hepatocellular
4
Biliary Tract Neoplasms
4
Gastrointestinal Neoplasms
3
Gastrinoma
3
Esophageal Squamous Cell Carcinoma
3
Carcinoma, Squamous Cell
3
Carcinoma, Renal Cell
3
Solid Tumor
2
Interventions
pembrolizumab
4
Cisplatin
4
Gemcitabine
3
Carboplatin
3
Docetaxel
2
Bupropion
2
tocilizumab
1
tislelizumab
1
spartalizumab
1
infigratinib
1
etoposide phosphate
1
cc-486
1
avelumab
1
Zoledronic Acid
1
Vorinostat
1
Varenicline
1
Tobacco Use Cessation Devices
1
Radiotherapy, Intensity-Modulated
1
Psychiatric Rehabilitation
1
Polymerase Chain Reaction
1
Pilocarpine
1
Oral Hygiene
1
Nivolumab
1
Nicotine Replacement Therapy
1
Nicotine
1
NVP-BKM120
1
Ifosfamide
1
Gene Expression Profiling
1
Fluorouracil
1
Fluorodeoxyglucose F18
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Nasopharyngeal Neoplasms
×
Capecitabine
×
Clear all
NCT02611960
2023-07-13
Keynote-122
Merck Sharp & Dohme LLC
Phase 3
Completed
233 enrolled
21 charts